Leaders in Genomic Diagnostics – GMDx Genomics has developed a genomic Platform Technology that uses validated algorithms to provide a detailed analysis of an individual’s Innate Immune Fitness.
The analysis of an individual’s Innate Immune Fitness provides the diagnostic ability to predict an individual’s capability to mount an effective Adaptive Immune Response in a range of disease states.
GMDx analyses a Whole Genome Sequence (WGS) from any laboratory source and provides a comprehensive genomic profile on that individual that is in full compliance with all health information privacy regulations.
GMDx utilises an industry-leading framework developed by technology stack partners Applied Precision Medicine that is built on the Oracle Autonomous Cloud
What We Do – Genomic analytics that enables better drug development, disease diagnosis and patient treatment.
Point of Difference – GMDx is the only company to specifically profile all DNA mutation signatures caused by dysfunction in the innate immune system. GMDx’s science is supported by a comprehensive patent portfolio commencing with filings in 2021 and other proprietary technology.
GMDx has developed a comprehensive and powerful genomic-profile test platform with the clinical applications in oncology for (i) predicting patient response to immunotherapy treatment and (ii) predicting cancer progression.
The GMDx platform technology combines proprietary predictive algorithms, a strong and extensive IP portfolio, sophisticated analytics, and machine learning capabilities that provides customers with clinical grade whole genome testing. Using a patient’s whole genome sequence GMDx has developed the Innate Immune Fitness (IIF) Profile. An individual’s Innate Immune system fitness provides the diagnostic ability to predict an individual’s capability to mount an effective Adaptive Immune Response in a range of disease states. Combined with the current state-of-the-art in cancer treatment, the GMDx IIF Profile provides a unique and innovative oncology solution.
Products in Oncology
- Predicting Cancer Progression
- Predicting Immuno-oncology responders/non-responders
- Genomic Data Services to optimise drug development
- Cognitive Impairment
Market size: US$39B
GMDx believes it currently qualifies under the Australian Tax Office (ATO) classification of an Early Stage Innovation Company (ESIC). Under this classification investors may be eligible for tax incentives in accordance with ‘Division 360 of the Income Tax Assessment Act 1997. Investors may be eligible for a tax offsets and capital gains relieve and should seek financial advice from their accountant or financial advisor in relation to potential ESIC benefits and before making any investment decision.
Capital Raise is for up to $1.7M.
Use of Funds
- Marketing of GMDx Data Services to support first revenues.
- Melanoma clinical study at the Alfred Hospital Melbourne (Australia).
- Intellectual property prosecution and expansion.
- Analytical platform expansion and information security.
- Support participation in clinical and commercial collaborations in USA and EU.
CEO & Director – 40 years in healthcare diagnostics, pharmaceuticals, bioinformatics, and medical devices
CSO & Director – Immunogeneticist, Science Director and Honorary Senior Fellow in Dept. of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne
CTO & Director – 18 years in healthcare, precision medicine, M&A, commercialisation, and compliance
CFO & Company Secretary – Fellow of CPA Australia, Chartered Global Management Accountant. CFO + CoSec of several ASX listed Companies